People taking adalimumab (Humira) for moderate-to-severe hidradenitis suppurativa (HS) saw better results across the board when the drug was combined with a surgical intervention. That's according to ...

Adalimumab in conjunction with surgery demonstrated more clinical effectiveness and improved quality of life in patients with hidradenitis suppurativa (HS) compared with outcomes in those treated with ...

Please provide your email address to receive an email when new articles are posted on . Patients achieved a reduction of 19.1 in HS severity when treated with combined surgery vs. a reduction of 7.8 ...

Exton, Pennsylvania, Jan. 10, 2024 (GLOBE NEWSWIRE) -- In late October 2023, the FDA granted approval to Novartis' Cosentyx (secukinumab) for treating hidradenitis suppurativa (HS), marking it as the ...

Last year, Financial Times reported that big pharma company Merck had attempted to acquire MoonLake for over $3 billion ...

Among adults treated with adalimumab, those with hidradenitis suppurativa (HS) showed a 53% higher risk for serious infections than adults with psoriasis, with notably increased risks for sepsis and ...

Swiss biotech firm, MoonLake Immunotherapeutics, saw its shares double after encouraging Phase 2 results for sonelokimab, a Nanobody therapy for inflammatory diseases. The MIRA trial revealed ...

"Adalimumab, regardless of HiSCR responder status, was associated with improvements in common hematologic abnormalities," the authors wrote, adding that "these findings highlight the high inflammatory ...